President Donald Trump recently issued an executive order to reclassify marijuana, moving it from Schedule I to Schedule III under the Controlled Substances Act. This decision, which acknowledges the medicinal potential of the plant, comes nearly four decades after Francis Young, a former chief administrative law judge at the Drug Enforcement Administration (DEA), originally argued against its placement in the most restrictive category.
Under the new classification, marijuana will be grouped with substances such as ketamine and Tylenol with codeine, which are recognized for legitimate medical use. This shift signals a significant change in federal policy, implicitly recognizing that the government has overstated the dangers of marijuana while overlooking its therapeutic benefits. Schedule I drugs, which include heroin and LSD, are classified as having a high potential for abuse and no accepted medical applications.
Since its classification in 1970, marijuana has faced numerous petitions for re-evaluation. Young’s pivotal ruling in 1988 stated that marijuana is “one of the safest therapeutically active substances known to man,” supporting its use under medical supervision for conditions like cancer-related nausea and multiple sclerosis spasticity. Despite this, the federal government upheld marijuana’s Schedule I status until a recent review by the Department of Health and Human Services (HHS), prompted by President Joe Biden, found substantial evidence for its medical use.
The HHS review highlighted “credible scientific support” for marijuana’s effectiveness in treating pain, nausea, vomiting, and conditions associated with medical illnesses. It noted that the majority of marijuana users do so without adverse consequences, leading to the conclusion that marijuana does not belong in Schedule I or even Schedule II, which includes substances like fentanyl and methamphetamine. The agency recommended that marijuana should be classified as Schedule III, a proposal accepted by Attorney General Merrick Garland in May 2024.
Trump’s announcement emphasized the potential relief for “American patients suffering from extreme pain, incurable diseases, aggressive cancers, seizure disorders, neurological problems and more.” The reclassification may enhance medical research opportunities by removing the stringent regulations imposed on Schedule I substances.
Despite the reclassification, marijuana’s medical use will not be legalized without specific approval from the Food and Drug Administration (FDA) for cannabis-based products. Additionally, state-licensed marijuana businesses will continue to operate under federal law as criminal enterprises, albeit with slightly reduced penalties due to the new classification. These businesses could, however, benefit from tax deductions that were previously unavailable under Schedule I, which imposed prohibitively high effective tax rates.
Since Young’s initial ruling, 40 states have legalized marijuana for medical use, with 24 states also permitting recreational use. This evolving landscape has created a legal conflict with federal prohibition, a policy increasingly opposed by the American public.
While Trump clarified that his order “doesn’t legalize marijuana in any way, shape or form,” the implications of this policy shift could reshape the future of cannabis legislation and its role in American healthcare.
